| scholarly article | Q13442814 |
| P50 | author | Mahmood Yaseen Hachim | Q89537664 |
| P2093 | author name string | Suad Hannawi | |
| Issa Al Salmi | |||
| Ibrahim Y Hachim | |||
| Haifa Hannawi | |||
| Kashif Bin Naeem | |||
| P2860 | cites work | Macrophages in rheumatoid arthritis | Q24806949 |
| Emerging role of chemokine CC motif ligand 4 related mechanisms in diabetes mellitus and cardiovascular disease: friends or foes? | Q26739691 | ||
| T Cell Migration in Rheumatoid Arthritis | Q26797338 | ||
| Leukocyte Trafficking in Cardiovascular Disease: Insights from Experimental Models | Q33561481 | ||
| Combination therapy for rheumatoid arthritis: methotrexate and sulfasalazine together or with other DMARDs | Q36897036 | ||
| Hydroxychloroquine: from malaria to autoimmunity | Q37827403 | ||
| CCL11, a novel mediator of inflammatory bone resorption | Q38679996 | ||
| Effects of antimalarial drugs on phospholipase A and lysophospholipase activities in plasma membrane, mitochondrial, microsomal and cytosolic subcellular fractions of rat liver | Q41916861 | ||
| Selective regulation of cytokine secretion by hydroxychloroquine: inhibition of interleukin 1 alpha (IL-1-alpha) and IL-6 in human monocytes and T cells. | Q41937744 | ||
| What is the future of CCR5 antagonists in rheumatoid arthritis? | Q42326321 | ||
| Chemotaxis of Vδ2 T cells to the joints contributes to the pathogenesis of rheumatoid arthritis. | Q47169048 | ||
| Regulation of CCR5 expression and MIP-1α production in CD4+ T cells from patients with rheumatoid arthritis | Q47969482 | ||
| Rheumatoid arthritis synovial tissue harbours dominant B-cell and plasma-cell clones associated with autoreactivity. | Q51053576 | ||
| CCR5 (chemokine receptor-5) DNA-polymorphism influences the severity of rheumatoid arthritis. | Q54020149 | ||
| BioJupies: Automated Generation of Interactive Notebooks for RNA-Seq Data Analysis in the Cloud | Q64121144 | ||
| CXCR3 and CCR5 ligands in rheumatoid arthritis synovium | Q73352970 | ||
| Impaired macrophage function and enhanced T cell-dependent immune response in mice lacking CCR5, the mouse homologue of the major HIV-1 coreceptor | Q74477278 | ||
| Eotaxin/CCL11 Levels Correlate With Myocardial Fibrosis and Mast Cell Density in Native and Transplanted Rat Hearts | Q85014745 | ||
| Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges | Q86910883 | ||
| Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology | Q89603158 | ||
| Clinical Characteristics of Coronavirus Disease 2019 in China | Q89934806 | ||
| Dysregulation of immune response in patients with COVID-19 in Wuhan, China | Q90251434 | ||
| Functional exhaustion of antiviral lymphocytes in COVID-19 patients | Q90589856 | ||
| COVID-19 infection and rheumatoid arthritis: Faraway, so close! | Q90602641 | ||
| Comparing the burdens of opportunistic infections among patients with systemic rheumatic diseases: a nationally representative cohort study | Q90659882 | ||
| A Rush to Judgment? Rapid Reporting and Dissemination of Results and Its Consequences Regarding the Use of Hydroxychloroquine for COVID-19 | Q90750837 | ||
| Tocilizumab treatment in COVID-19: A single center experience | Q91615442 | ||
| CCR5 silencing reduces inflammatory response, inhibits viability, and promotes apoptosis of synovial cells in rat models of rheumatoid arthritis through the MAPK signaling pathway | Q91841715 | ||
| Hydroxychloroquine and covid-19 | Q91968915 | ||
| Cytokine storm and immunomodulatory therapy in COVID-19: role of chloroquine and anti-IL-6 monoclonal antibodies | Q92038834 | ||
| Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis | Q92331107 | ||
| Serious infection risk in rheumatoid arthritis compared with non-inflammatory rheumatic and musculoskeletal diseases: a US national cohort study | Q93064067 | ||
| Rethinking the role of hydroxychloroquine in the treatment of COVID-19 | Q94463058 | ||
| Efficacy of chloroquine and hydroxychloroquine in the treatment of COVID-19 | Q94566536 | ||
| Full-length title: Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France | Q94589521 | ||
| Immune cell profiling of COVID-19 patients in the recovery stage by single-cell sequencing | Q94595300 | ||
| Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19 | Q94600823 | ||
| The immunology of COVID-19: is immune modulation an option for treatment? | Q95637970 | ||
| COVID-19 in an HIV-positive Kidney Transplant Recipient | Q95843782 | ||
| Alveolar macrophage dysfunction and cytokine storm in the pathogenesis of two severe COVID-19 patients | Q96648865 | ||
| CCR5 Δ32 minorallele is associated with susceptibility to SARS-CoV-2 infection and death: An epidemiological investigation | Q97550828 | ||
| Contribution of monocytes and macrophages to the local tissue inflammation and cytokine storm in COVID-19: Lessons from SARS and MERS, and potential therapeutic interventions | Q97597522 | ||
| P433 | issue | 1 | |
| P921 | main subject | rheumatoid arthritis | Q187255 |
| in silico | Q192572 | ||
| COVID-19 | Q84263196 | ||
| P304 | page(s) | 14 | |
| P577 | publication date | 2020-09-09 | |
| P1433 | published in | Translational Medicine Communications | Q50817370 |
| P1476 | title | C-C chemokine receptor type 5 links COVID-19, rheumatoid arthritis, and Hydroxychloroquine: in silico analysis | |
| P478 | volume | 5 |
Search more.